Actuate Therapeutics Inc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ACTU research report →
Range $21 – $21
Price Chart
About the company
Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating treatments for various cancers. Its primary drug candidate is Elraglusib Injection, an innovative glycogen synthase kinase-3 (GSK-3) inhibitor designed to combat metastatic pancreatic ductal adenocarcinoma.
- CEO
- Daniel Schmitt
- IPO
- 2024
- Employees
- 12
- HQ
- Fort Worth, TX, US
Get TickerSpark's AI analysis on ACTU
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $19.77M
- P/E
- -0.93
- Fwd P/E
- 0.65
- PEG
- -0.01
- P/S
- 0.00
- P/B
- 19.94
- EV/EBITDA
- -0.77
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -346.18%
- ROIC
- -1489.99%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-22,495,312
- Net Income
- $-22,227,852+18.5%
- EPS
- $-1.06+67.5%
- OCF Growth
- +12.1%
- FCF Growth
- +12.1%
- 52W High
- $8.49
- 52W Low
- $0.60
- 50D MA
- $1.11
- 200D MA
- $2.71
- Beta
- 0.78
- RSI (14)
- 43
- Avg Volume
- 381.59K
No earnings-call transcripts are available for ACTU yet.
- Free Float
- 35.8%
- Shares Outstanding
- 23.93M
- Float Shares
- 8.57M
of shares held by institutions
61 13F filers
Buy/sell ratio 0.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Bios Capital Management, LP | 10.05M | 0 |
| Voss Capital, LLC | 1.73M | 0 |
| Vanguard Group Inc | 529.11K | ▲ 213.10K |
| Vanguard Capital Management LLC | 393.43K | ▼ 7.10K |
| Aqr Capital Management LLC | 127.49K | ▲ 100.38K |
| Geode Capital Management, LLC | 112.55K | ▼ 115.78K |
| Texas Capital Bank Wealth Management Services Inc | 102.61K | ▲ 8.02K |
| Palogic Value Management, L.P. | 100.00K | 0 |
| Millennium Management LLC | 96.68K | ▲ 96.68K |
| Blackrock, Inc. | 90.03K | ▼ 337.12K |
| Abs Direct Equity Fund LLC | 73.19K | ▲ 23.19K |
| Abs Investment Management LLC | 73.19K | ▲ 73.19K |
Held by 25 ETFs
Biggest fund positions in ACTU by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 14, 26 | SCHMITT DANIEL M | other | 272,056 |
| Aug 14, 26 | SCHMITT DANIEL M | other | 120,521 |
| Aug 14, 26 | SCHMITT DANIEL M | other | 272,056 |
| May 21, 26 | Zabrowski Dan | other | 15,000 |
| May 21, 26 | THOMSON TODD S | other | 15,000 |
| May 21, 26 | Sawhney Roger | other | 15,000 |
| May 21, 26 | RONNEBERG AMY L | other | 15,000 |
| May 21, 26 | Keyes Jason A | other | 15,000 |
| May 21, 26 | Huber Martin H. Jr. | other | 15,000 |
| May 21, 26 | Fletcher Aaron G.L. | other | 15,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ACTU coverage
Recent articles, reports, and earnings notes.
No research on ACTU yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ACTU report →Actuate to Present at the H.C. Wainwright 28th Annual Global Investment Conference
globenewswire.com · Sep 9
Actuate Announces Promising Preclinical Data Showing Synergistic Activity of Elraglusib in Combination with RAS Inhibitors Zoldonrasib and Daraxonrasib
globenewswire.com · Sep 9
All You Need to Know About Actuate Therapeutics, Inc. (ACTU) Rating Upgrade to Buy
zacks.com · Sep 2
Actuate Therapeutics' Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma
globenewswire.com · Jun 9
Actuate Therapeutics Announces ASCO Poster Presentations Demonstrating Compelling Clinical and Biomarker Data for Elraglusib in First-Line Metastatic Pancreatic Cancer
globenewswire.com · Jun 1
Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program
globenewswire.com · May 11
Analysts see 200%+ upside in these 3 high-risk stocks: here's why?
invezz.com · May 9
Actuate Therapeutics Announces Key Appointment of Industry Veteran to Board of Directors
globenewswire.com · May 6
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.